A $107 Million Bet on Europe's Next Generation of Medical Tech

Jan de Vries · 2026-08-31

Let's talk about a major move in European healthcare innovation. Stockholm-based Elekta, a heavyweight in precision radiation medicine, just secured a significant financial boost. We're looking at a loan of up to $107 million from the European Investment Bank (EIB). That's a lot of trust placed in one company. But here's the thing – it's not just about one firm. This financing is part of the EIB's broader TechEU program. Think of it as Europe's strategic playbook. The goal is to double down on homegrown innovation, especially in areas that matter most: health research and cutting-edge medical technology. As Karl Nehammer, Vice-President at the EIB, put it, "Europe has world-leading medical-technology companies and we need to make sure they can continue investing and innovating here. This financing will support the next generation of cancer and neurological treatments." ### What This Financing Actually Funds So, where's all that money going? The EIB loan is set to cover about half of a massive research program Elekta has planned. We're talking a total investment of roughly $214 million between 2026 and 2029. Most of this groundbreaking work will happen right where the expertise is, in Sweden and the Netherlands. It's a timely injection of capital. In 2025 alone, the EIB Group signed over $107 billion in new financing across more than 870 projects. Their focus is clear: climate action, digitalization, security, and social infrastructure. Health tech sits right at the heart of that mission. ### Who Is Elekta, Anyway? You might not know the name, but their impact is global. Founded back in 1972 by Lars and Laurent Leksell and listed on Nasdaq Stockholm, this company has been in the fight against cancer for decades. They develop the sophisticated systems used for treating a daunting range of cancers: - Brain tumours - Breast cancer - Kidney and lung cancer - Pancreatic and prostate cancer They also tackle certain neurological disorders. Their approach hinges on three pillars: adaptive radiotherapy, precision treatment delivery, and integrated clinical workflows. The scale is staggering – their technology treats more than 2 million patients every single year. With around 4,000 employees and a presence in over 40 countries, they're a true European success story selling into 120 markets worldwide. ### The Real-World Impact Klara Eiritz, Elekta's CFO, connected the dots between finance and frontline care. "As demand for cancer care continues to grow, healthcare providers are looking for solutions that help them treat more patients while maintaining quality and precision," she said. This financing, she explained, provides the flexibility to support their long-term strategy. It's all about fueling innovation that improves clinical outcomes, boosts operational efficiency, and, most importantly, enhances the patient experience. The funding will specifically back Elekta's work across several critical areas: - Radiotherapy - Radiosurgery - Brachytherapy - The software platforms that plan and deliver these complex therapies The aim is to improve treatment for conditions like brain and body tumours, essential tremor, and certain forms of epilepsy. In short, they want to make treatments more accurate and efficient, helping clinics handle a growing number of patients without compromising care. ### A Trend in European HealthTech This isn't an isolated deal. It follows a pattern of EIB-backed support for European health tech innovators. Just last July, the EIB signed a $21.4 million venture debt agreement with Aiforia, a Finnish digital pathology firm. It signals a concerted effort to build and retain Europe's technological sovereignty in critical sectors. For professionals watching the EU startup and incorporation landscape, deals like this are more than just news. They're indicators of where strategic capital is flowing. They highlight the sectors deemed vital for competitiveness and showcase the financial instruments, like the TechEU program, that are actively shaping the market. It begs the question: which European medtech champion will be next to secure this kind of strategic backing?